Mass General Brigham Ventures, Alphabet-backed GV and General Catalyst are all part of a $32 million seed funding round for Rippl, a tech-driven mental healthcare company focused on older adults.
Category: ROOT
Humana’s 3rd-party vendor breach affects 22,767 patients
Choice Health, the company used to help Humana sell its products, experienced a data breach that resulted in the protected health information of 22,767 patients being compromised.
When does this count as a crisis, physicians ask of capacity issues at children’s hospitals
Children’s hospitals across the U.S. are being inundated with patients sick with respiratory viruses.
These are the largest U.S counties with the most medical debt
Texas counties have the highest percentage of residents with medical debt out of the country’s 20 largest counties, according to a Kaiser Health News analysis of Urban Credit Institute data.
Texas hospital restores clinical systems 3 weeks after cyberattack
Richmond, Texas-based OakBend Medical Center has almost completely restored its clinical systems after a Sept. 1 ransomware attack took them offline.
DEA seizes 10M pills laced with fentanyl
A year into its One Pill Can Kill initiative, the Justice Department’s Drug Enforcement Administration has seized the equivalent of more than 36 million lethal doses of fentanyl between May 23 and Sept. 8.
How nursing schools are tackling high nurse practitioner demandÂ
Nursing schools are enacting changes to their programs to meet the high demand for nurse practitioners, Fortune reported Sept. 27.
9 hospitals have closed this year — here’s why
From cash flow and staffing challenges to dwindling patient volumes, many factors lead hospitals to shut down.
Reliance on single-use devices leads to supply chain disruptions, HHS report says
A Department of Health and Human Services report found single-use medical devices account for most of hospital greenhouse gas emissions and lead to supply chain disruptions.
Biogen’s Alzheimer’s drug slowed cognitive decline by 27%
Following Biogen’s recent failure of Aduhelm and a CEO resignation on the horizon, the drugmaker’s new Alzheimer’s drug candidate showed promising results in a phase 3 trial with a 27 percent slower cognitive decline.
